The funds, raised through a private placement of 60 million shares at A$.195 per share will be used to fund "acquisition growth" and the roll-out of its BrevaGen test in the US.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.